Dr Patrick McManamny (pictured) and Dr Marcus Caulfield have been promoted to partner in the firm’s biotechnology and chemistry practice.
\Both McManamny and Caulfield joined FB Rice in 2002.They act for a broad range of clients, including international corporations, start-up companies, universities, hospitals, co-operative research centres and research institutes.
McManamny is a member of the biotechnology team and counsels clients in relation to management of international patent portfolios, freedom-to-operate and validity of patents. His practice primarily focuses on biological therapeutics, such as antibodies, peptides and stem cells. He also has expertise in diagnostics and drug-screening technologies.
“I am delighted to be joining the dynamic and forward-looking partnership of FB Rice. I look forward to continuing to be a part of our firm, which is recognised as being innovative in its approach to client matters and as having a strong commercial perspective,” said McManamny.
Caulfield has a strong technical background in organic and polymer chemistry and has worked extensively with both animal and human healthcare areas with a strong emphasis on contentious matters including opposition and litigation support.
Managing partner Dr Brett Lunn said: “Patrick and Marcus’ strategic and solutions-driven approach is what clients are looking for. With their extensive experience, both are very well placed to continue providing intelligent, well-considered, strategic advice to help clients protect their intellectual property.”